{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T20:59:21Z","timestamp":1782421161021,"version":"3.54.5"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T00:00:00Z","timestamp":1722729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.esmogo.2024.100092","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T09:19:15Z","timestamp":1725009555000},"page":"100092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["New perspectives in biliary tract cancers"],"prefix":"10.1016","volume":"5","author":[{"given":"T.O.","family":"Goetze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Roderburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-9445","authenticated-orcid":false,"given":"F.W.","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9414-378X","authenticated-orcid":false,"given":"J.","family":"Trojan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmogo.2024.100092_bib1","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.2217\/fon-2021-1302","article-title":"Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety","volume":"18","author":"Khankhel","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.21037\/cco.2016.10.09","article-title":"Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations","volume":"5","author":"Marcano-Bonilla","year":"2016","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib3","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3390\/cancers12051237","article-title":"Biliary tract cancer: current medical treatment strategies","volume":"12","author":"Oneda","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.esmogo.2024.100092_bib4","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.esmogo.2024.100092_bib5","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.esmogo.2024.100092_bib6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib7","series-title":"NCCN Guidelines Version 2.2024 - Biliary Tract Cancers","year":"2024"},{"key":"10.1016\/j.esmogo.2024.100092_bib8","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmogo.2024.100092_bib9","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmogo.2024.100092_bib10","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.3390\/cancers12113370","article-title":"Biliary tract cancers: molecular heterogeneity and new treatment options","volume":"12","author":"Personeni","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.esmogo.2024.100092_bib11","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.3390\/cancers14163921","article-title":"Diagnosis biomarkers of cholangiocarcinoma in human bile: an evidence-based study","volume":"14","author":"Bao","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.esmogo.2024.100092_bib12","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.3390\/cancers13133222","article-title":"Next-generation biomarkers for cholangiocarcinoma","volume":"13","author":"Rodrigues","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.esmogo.2024.100092_bib13","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2147\/IJGM.S297371","article-title":"Serum microRNAs as biomarkers for the noninvasive early diagnosis of biliary tract cancer","volume":"14","author":"Han","year":"2021","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.esmogo.2024.100092_bib14","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.esmogo.2024.100092_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.21037\/jgo.2016.10.01","article-title":"Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications","volume":"8","author":"Ahn","year":"2017","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib16","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1200\/JCO.2023.41.16_suppl.4008","article-title":"Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC)","volume":"41","author":"Pant","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib17","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib18","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmogo.2024.100092_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920953293","article-title":"FGFR inhibitors in cholangiocarcinoma: what\u2019s now and what\u2019s next?","volume":"12","author":"Saborowski","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.esmogo.2024.100092_bib21","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41416-022-01908-1","article-title":"Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing","volume":"127","author":"Neumann","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmogo.2024.100092_bib22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.esmogo.2024.100092_bib23","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib24","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.12998\/wjcc.v7.i14.1732","article-title":"Diagnostic-therapeutic management of bile duct cancer","volume":"7","author":"Huguet","year":"2019","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.esmogo.2024.100092_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102170","article-title":"Targeting FGFR inhibition in cholangiocarcinoma","volume":"95","author":"Goyal","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmogo.2024.100092_bib26","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmogo.2024.100092_bib27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41698-021-00204-0","article-title":"Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer","volume":"5","author":"Nakamura","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib28","doi-asserted-by":"crossref","first-page":"751","DOI":"10.21037\/jgo.2019.03.10","article-title":"Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review","volume":"10","author":"Boscoe","year":"2019","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib29","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","article-title":"Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles","volume":"18","author":"Farshidfar","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.esmogo.2024.100092_bib30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/1078-0432.CCR-14-3296","article-title":"Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma","volume":"22","author":"Moeini","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmogo.2024.100092_bib31","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2022.40.16_suppl.4079","article-title":"Targeting HER2 mutation\u2013positive advanced biliary tract cancers with neratinib: final results from the phase 2 SUMMIT basket trial","volume":"40","author":"Harding","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib32","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.2169\/internalmedicine.4588-20","article-title":"Microsatellite instability-high intrahepatic cholangiocarcinoma with portal vein tumor thrombosis successfully treated with pembrolizumab","volume":"59","author":"Naganuma","year":"2020","journal-title":"Int Med"},{"key":"10.1016\/j.esmogo.2024.100092_bib33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/13543784.2021.1896703","article-title":"Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers","volume":"30","author":"Boil\u00e8ve","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.esmogo.2024.100092_bib34","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib35","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). Diagnostik und Therapie des Hepatozellul\u00e4ren Karzinoms und bili\u00e4rer Karzinome Langversion 4.0. WMF-Registernummer: 032\/053OL ed2023."},{"key":"10.1016\/j.esmogo.2024.100092_bib36","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2017.10.013","article-title":"Precision medicine for patients with advanced biliary tract cancers: an effective strategy within the prospective MOSCATO-01 trial","volume":"87","author":"Verlingue","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmogo.2024.100092_bib37","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.esmogo.2024.100092_bib38","unstructured":"Sinn M, Arnold D, Borner M, et\u00a0al. Onkopedia Leitlinie: Bili\u00e4re Karzinome - Karzinome der Galleng\u00e4nge und Gallenblase. Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Medizinische Onkologie eV.\u00a02024."},{"key":"10.1016\/j.esmogo.2024.100092_bib39","series-title":"Biliary Tract Cancer","author":"Zamani","year":"2022"},{"key":"10.1016\/j.esmogo.2024.100092_bib40","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1007\/s00464-011-2044-z","article-title":"The prognostic impact of positive lymph nodes in stages T1 to T3 incidental gallbladder carcinoma: results of the German Registry","volume":"26","author":"Goetze","year":"2012","journal-title":"Surg Endosc"},{"key":"10.1016\/j.esmogo.2024.100092_bib41","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1245\/s10434-009-0777-x","article-title":"Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option","volume":"17","author":"Saxena","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib42","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1055\/s-0039-1696649","article-title":"Ablation of intrahepatic cholangiocarcinoma","volume":"36","author":"Sweeney","year":"2019","journal-title":"Semin Intervent Radiol"},{"key":"10.1016\/j.esmogo.2024.100092_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e16150","article-title":"A\u00a0pilot study of the combination of checkpoint inhibition with ablation in subjects with biliary tract cancer","volume":"39","author":"Wetzel","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","article-title":"Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial","volume":"6","author":"Edeline","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib45","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1159\/000525489","article-title":"Selective internal radiation therapy with Yttrium-90 resin microspheres followed by gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma: a phase 2 single-arm multicenter clinical trial","volume":"11","author":"Chan","year":"2022","journal-title":"Liver Cancer"},{"key":"10.1016\/j.esmogo.2024.100092_bib47","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2147\/OTT.S79316","article-title":"Transcatheter arterial chemoembolization with gemcitabine and oxaliplatin for the treatment of advanced biliary tract cancer","volume":"8","author":"Zhao","year":"2015","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.esmogo.2024.100092_bib48","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.21873\/anticanres.11522","article-title":"Chemoembolization with drug-eluting microspheres loaded with doxorubicin for the treatment of cholangiocarcinoma","volume":"37","author":"Aliberti","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.esmogo.2024.100092_bib49","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1055\/s-0037-1602591","article-title":"Decision making: intra-arterial therapies for cholangiocarcinoma-TACE and TARE","volume":"34","author":"Currie","year":"2017","journal-title":"Semin Intervent Radiol"},{"key":"10.1016\/j.esmogo.2024.100092_bib50","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00270-021-02800-w","article-title":"Transarterial chemoembolization and radioembolization for unresectable intrahepatic cholangiocarcinoma-a systemic review and meta-analysis","volume":"44","author":"Mosconi","year":"2021","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.esmogo.2024.100092_bib51","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1159\/000518298","article-title":"Adjuvant radiotherapy for extrahepatic cholangiocarcinoma: a quality assessment-based meta-analysis","volume":"10","author":"Choi","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.esmogo.2024.100092_bib52","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ctrv.2011.05.003","article-title":"Is adjuvant radiotherapy needed after curative resection of extrahepatic biliary tract cancers? A systematic review with a meta-analysis of observational studies","volume":"38","author":"Bonet Beltr\u00e1n","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmogo.2024.100092_bib53","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1200\/jco.2011.29.15_suppl.4050","article-title":"Adjuvant therapy in the treatment of biliary tract cancer (BTC): a systematic review and meta-analysis","volume":"29","author":"Horgan","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.604387","article-title":"The evolving role of radiation therapy in the treatment of biliary tract cancer","volume":"10","author":"Gkika","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib55","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1245\/s10434-022-11439-x","article-title":"Hepatic arterial infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis","volume":"29","author":"Holster","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib56","series-title":"PEARLDIFER: a phase II study of pemigatinib in combination with SBRT (Stereotactic Body Radiation Therapy) as definitive organ preserving therapy in locally advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions\/rearrangements","author":"G\u00f6tze","year":"2022"},{"key":"10.1016\/j.esmogo.2024.100092_bib57","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1200\/JCO.2024.42.16_suppl.4006","article-title":"Addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in locally advanced cholangiocarcinoma (CC) (ABC-07): results from a randomized phase II trial","volume":"42","author":"Hawkins","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib58","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jamasurg.2020.1973","article-title":"Very early recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches","volume":"155","author":"Tsilimigras","year":"2020","journal-title":"JAMA Surg"},{"key":"10.1016\/j.esmogo.2024.100092_bib59","first-page":"73","article-title":"A\u00a0review of current adjuvant and neoadjuvant systemic treatments for cholangiocarcinoma and gallbladder carcinoma","volume":"7","author":"Allen","year":"2021","journal-title":"Hepatoma Res"},{"key":"10.1016\/j.esmogo.2024.100092_bib60","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s12885-015-1498-0","article-title":"Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial","volume":"15","author":"Stein","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmogo.2024.100092_bib61","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib62","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.3390\/cancers13071647","article-title":"Current status and future perspectives of perioperative therapy for resectable biliary tract cancer: a multidisciplinary review","volume":"13","author":"Yoo","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.esmogo.2024.100092_bib63","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1200\/JCO.2022.40.4_suppl.382","article-title":"Adjuvant S-1 versus observation in curatively resected biliary tract cancer: a phase III trial (JCOG1202: ASCOT)","volume":"40","author":"Ikeda","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib64","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS4187","article-title":"ADJUBIL: a phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer","volume":"41","author":"Goetze","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib65","article-title":"Phase 2 study of preoperative gemcitabine plus cisplatin with durvalumab (MEDI4736) and tremelimumab in intrahepatic cholangiocarcinoma (NeoTreme)","author":"Marquardt","year":"2023","journal-title":"German Clinical Trials Register"},{"key":"10.1016\/j.esmogo.2024.100092_bib66","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1200\/JCO.2017.35.4_suppl.225","article-title":"Gemox versus surveillance following surgery of localized biliary tract cancer: results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial","volume":"35","author":"Edeline","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib67","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s12094-021-02573-1","article-title":"SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)","volume":"23","author":"G\u00f3mez-Espa\u00f1a","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib68","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmogo.2024.100092_bib69","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA490","article-title":"SWOG 1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers","volume":"41","author":"Shroff","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib70","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.21.00679","article-title":"Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): a randomized phase II study","volume":"40","author":"Phelip","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib71","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","article-title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial","volume":"30","author":"Morizane","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib72","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)","volume":"30","author":"Ioka","year":"2023","journal-title":"J\u00a0Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.esmogo.2024.100092_bib73","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2022.40.16_suppl.4070","article-title":"Patient-reported outcomes for the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"40","author":"Burris","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib74","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1016\/j.annonc.2022.07.084","article-title":"56P updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)","volume":"33","author":"Oh","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib75","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1200\/JCO.2024.42.16_suppl.4093","article-title":"Three-year follow-up data from KEYNOTE-966: pembrolizumab (pembro) plus gemcitabine and cisplatin (gem\/cis) compared with gem\/cis alone for patients (pts) with advanced biliary tract cancer (BTC)","volume":"42","author":"Finn","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib76","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib77","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib78","doi-asserted-by":"crossref","first-page":"v876","DOI":"10.1093\/annonc\/mdz394.031","article-title":"FIGHT-202: a phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)","volume":"30","author":"Vogel","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib79","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/JCO.2021.39.3_suppl.265","article-title":"Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement","volume":"39","author":"Javle","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib80","doi-asserted-by":"crossref","first-page":"S1461","DOI":"10.1016\/j.annonc.2022.10.112","article-title":"76MO efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f\/r), FGFR inhibitor (FGFRi)-naive cholangiocarcinoma (CCA): ReFocus trial","volume":"33","author":"Park","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib82","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.23.00606","article-title":"Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer (SGNTUC-019): a phase II basket study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib83","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.esmogo.2024.100092_bib84","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1200\/JCO.2022.40.16_suppl.4006","article-title":"Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): an investigator-initiated multicenter phase 2 study (HERB trial)","volume":"40","author":"Ohba","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib85","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00280-009-0927-7","article-title":"A\u00a0phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer","volume":"64","author":"Ramanathan","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.esmogo.2024.100092_bib86","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.23.01193","article-title":"Trastuzumab plus gemcitabine-cisplatin for treatment-na\u00efve human epidermal growth factor receptor 2-positive biliary tract adenocarcinoma: a multicenter, open-label, phase II study (TAB)","volume":"42","author":"Ostwal","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib87","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2147\/CMAR.S157156","article-title":"Biliary tract cancer: current challenges and future prospects","volume":"11","author":"Ghidini","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.esmogo.2024.100092_bib88","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1586\/egh.10.45","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"4","author":"Weigt","year":"2010","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.esmogo.2024.100092_bib89","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmogo.2024.100092_bib90","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmogo.2024.100092_bib91","doi-asserted-by":"crossref","unstructured":"Oh D-Y, He AR, Qin S, et\u00a0al. Three-year survival and safety update from the Phase 3 TOPAZ-1 study of durvalumab plus chemotherapy in biliary tract cancer. Paper presented at the Annual Cholangiocarcinoma Foundation Conference, May 8\u201310, 2024;11.","DOI":"10.1080\/VJBM-2023-0017-media"},{"key":"10.1016\/j.esmogo.2024.100092_bib92","series-title":"Referenced with Permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-small Cell Lung Cancer V1 (2019)","year":"2020"},{"key":"10.1016\/j.esmogo.2024.100092_bib93","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S1470-2045(21)00486-1","article-title":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study","volume":"22","author":"Yoo","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib94","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S2468-1253(24)00119-5","volume":"9","author":"Vogel","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.esmogo.2024.100092_bib95","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib96","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2217\/fon-2020-0429","article-title":"FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements","volume":"16","author":"Bekaii-Saab","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib97","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib98","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an irreversible FGFR1\u20134 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmogo.2024.100092_bib99","doi-asserted-by":"crossref","first-page":"CT010","DOI":"10.1158\/1538-7445.AM2021-CT010","article-title":"Abstract CT010: Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions\/rearrangements","volume":"81","author":"Goyal","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmogo.2024.100092_bib100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.4_suppl.TPS600","volume":"38","author":"Borad","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib101","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/2159-8290.CD-21-1168","article-title":"EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion\u2013positive cholangiocarcinoma","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmogo.2024.100092_bib102","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmogo.2024.100092_bib103","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmogo.2024.100092_bib104","article-title":"Noninvasive detection of polyclonal acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations","volume":"5","author":"Varghese","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib105","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1200\/JCO.2023.41.4_suppl.539","article-title":"Phase II study of FGFR1-3 inhibitor tinengotinib as monotherapy in patients with advanced or metastatic cholangiocarcinoma: interim analysis","volume":"41","author":"Javle","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib106","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib107","doi-asserted-by":"crossref","first-page":"S459","DOI":"10.1016\/j.annonc.2023.09.1840","article-title":"Efficacy and safety of trastuzumab deruxtecan (T-DXD) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): primary results from the international phase 2 DESTINY-PanTumor01 (DPT-01) study","volume":"34","author":"Li","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmogo.2024.100092_bib108","series-title":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","year":"2023"},{"key":"10.1016\/j.esmogo.2024.100092_bib109","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12885-020-6610-4","volume":"20","author":"Goetze","year":"2020","journal-title":"BMC Cancer"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819824000530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819824000530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:25:04Z","timestamp":1762651504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819824000530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":108,"alternative-id":["S2949819824000530"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2024.100092","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New perspectives in biliary tract cancers","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2024.100092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100092"}}